Joseph G. Pressey · Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)
Follow
Article1 min read·Published Jul 2019Older

Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Jul 2019 · 1 min read

In brief

In brief

Phase II trial evaluating everolimus plus bevacizumab in 25 patients with refractory MPNST (17 NF1-related, 8 sporadic) achieved only 12% clinical benefit rate, falling short of the 25% target. The mTOR/angiogenesis inhibitor combination is not considered active for this indication despite biological rationale.

Written by the GCMD Library team from the article.

Joseph G. Pressey

Purpose: There are no known effective medical treatments for refractory MPNST. Inactivation of the NF1 tumor suppressor in MPNST results in upregulation of mTOR (mammalian target of rapamycin) signaling and angiogenesis, which contributes to disease progression. We conducted a phase II study for patients (pts) with refractory MPNST combining everolimus (10 mg PO once daily) with bevacizumab (10 mg/kg IV every 2 weeks) to determine the clinical benefit rate (CBR) (complete response, partial response (PR), or stable disease (SD) ≥ 4 months). Patients And Methods: Patients ≥18 years old with chemotherapy refractory sporadic or NF1 MPNST were eligible. Tumor response was assessed after every 2 cycles (the WHO criteria). A two-stage design targeting a 25% CBR was used: if ≥ 1/15 pts in stage 1 responded, enrollment would be expanded by 10 pts, and if ≥ 4/25 patients had clinical benefit, the combination would be considered active. Results: Twenty-five pts, 17 with NF1 and 8 with sporadic MPNST, enrolled. One of 15 pts in stage 1 had clinical benefit. Of 10 additional pts enrolled, 2 had clinical benefit. The median number of completed cycles was 3 (range 1-16). Adverse events were similar to those known for this combination. Conclusion: With a CBR of 12% (3/25), the combination of everolimus and bevacizumab did not reach the study's target response rate and is not considered active in refractory MPNST.

Statements in this article

  1. There are no known effective medical treatments for refractory MPNST.

    EstablishedPurpose
  2. Inactivation of the NF1 tumor suppressor in MPNST results in upregulation of mTOR signaling and angiogenesis, which contributes to disease progression.

    EstablishedPurpose
  3. Everolimus was administered at 10 mg PO once daily in combination with bevacizumab 10 mg/kg IV every 2 weeks.

    RecommendationPurpose
  4. Clinical benefit rate was defined as complete response, partial response, or stable disease for at least 4 months.

    EstablishedPurpose
  5. Patients 18 years or older with chemotherapy refractory sporadic or NF1 MPNST were eligible for enrollment.

    RecommendationPatients And Methods
  6. Tumor response was assessed after every 2 cycles using the WHO criteria.

    RecommendationPatients And Methods
  7. The study used a two-stage design targeting a 25% clinical benefit rate, requiring at least 1 of 15 patients in stage 1 to respond for expansion and at least 4 of 25 patients to have clinical benefit for the combination to be considered active.

    EstablishedPatients And Methods
  8. Twenty-five patients enrolled, including 17 with NF1 and 8 with sporadic MPNST.

    ResearchResults
  9. One of 15 patients in stage 1 had clinical benefit.

    ResearchResults
  10. Two of 10 additional patients enrolled in stage 2 had clinical benefit.

    ResearchResults
  11. The median number of completed cycles was 3, with a range of 1 to 16 cycles.

    ResearchResults
  12. The clinical benefit rate was 12% (3 of 25 patients).

    ResearchConclusion
  13. The combination of everolimus and bevacizumab did not reach the study's target response rate and is not considered active in refractory MPNST.

    ResearchConclusion

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.